Tempest Therapeutics announces agreement with Roche for amezalpat combo therapy

Tempest Therapeutics (TPST) announced an agreement with Roche (RHHBY) to advance the evaluation of amezalpat, TPST-1120, in combination with atezolizumab and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma, into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need. Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.